title: Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients.
abstract: OBJECTIVE
  There is an urgent need for markers that can predict the efficacy of adjuvant chemotherapy in patients with solid tumors. This study was designed to evaluate whether monitoring of micrometastases in bone marrow can predict the response to systemic chemotherapy in breast cancer.
  
  
  METHODS
  Bone marrow aspirates of 59 newly diagnosed breast cancer patients with either inflammatory (n = 23) or advanced (> four nodes involved) disease (n = 36) were examined immunocytochemically with the monoclonal anticytokeratin (CK) antibody A45-B/B3 (murine immunoglobulin G(1); Micromet, Munich, Germany) before and after chemotherapy with taxanes and anthracyclines.
  
  
  RESULTS
  Of 59 patients, 29 (49.2%) and 26 (44.1%) presented with CK-positive tumor cells in bone marrow before and after chemotherapy, respectively. After chemotherapy, less than half of the previously CK-positive patients (14 of 29 patients; 48.3%) had a CK-negative bone marrow finding, and 11 (36. 7%) of 30 previously CK-negative patients were CK-positive. At a median follow-up of 19 months (range, 6 to 39 months), Kaplan-Meier analysis of 55 assessable patients revealed a significantly reduced overall survival (P =.011; log-rank test) if CK-positive cells were detected after chemotherapy. In multivariate analysis, the presence of CK-positive tumor cells in bone marrow after chemotherapy was an independent predictor for reduced overall survival (relative risk = 5.0; P =.016).
  
  
  CONCLUSIONS
  The cytotoxic agents currently used for chemotherapy in high-risk breast cancer patients do not completely eliminate CK-positive tumor cells in bone marrow. The presence of these tumor cells after chemotherapy is associated with poor prognosis. Thus, bone marrow monitoring might help predict the response to systemic chemotherapy.
authors.affiliation: I. Frauenklinik der Ludwig-Maximilians-Universität, Munich, Germany. Sbraun@fk-i.med.uni-muenchen.de
authors.forename: S
authors.initials: S
authors.lastname: Braun
authors.forename: C
authors.initials: C
authors.lastname: Kentenich
authors.forename: W
authors.initials: W
authors.lastname: Janni
authors.forename: F
authors.initials: F
authors.lastname: Hepp
authors.forename: J
authors.initials: J
authors.lastname: de Waal
authors.forename: F
authors.initials: F
authors.lastname: Willgeroth
authors.forename: H
authors.initials: H
authors.lastname: Sommer
authors.forename: K
authors.initials: K
authors.lastname: Pantel
mesh_terms: D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000032:analysis; D008875:Middle Aged; D015999:Multivariate Analysis; D009362:Neoplasm Metastasis; D018365:Neoplasm, Residual; D011379:Prognosis; D012044:Regression Analysis; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D007633:Keratins